DSIP
A small endogenous research peptide associated with sleep physiology, with uncertain therapeutic relevance.
On this page
WHAT THE EVIDENCE SAYS
DSIP evidence summary.
DSIP's therapeutic reputation rests on very small historical studies and uncertain physiology, not on a modern clinical development program.
01 / CLASSIFICATION
What is DSIP?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
DSIP human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
DSIP FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is DSIP being studied for?
05 / COMPARISONS
Compare DSIP.
06 / LATEST & DEFINING SOURCES
DSIP primary and official sources.
07 / QUESTIONS
Questions about DSIP.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
DSIP's therapeutic reputation rests on very small historical studies and uncertain physiology, not on a modern clinical development program.
Current source-backed research areas include Sleep physiology, Stress response, Neuropeptide identity, Electroencephalography. These areas describe investigation, not established personal benefit.
Current U.S. status for DSIP: No FDA-approved DSIP drug product; FDA enforcement records have described DSIP products as unapproved new drugs.
Current sport-status snapshot for DSIP: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
A peptide name linked to sleep does not establish that a marketed product improves insomnia or sleep quality.